Skip to main content

Table 1 Difference in baseline clinical and angiographic characteristics among the MACE and non-MACE group of study population (total population)

From: The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China

CharacteristicsMACE (n = 483)Non-MACE (n = 1873)P value
Demographic
 Age, years58.03 ± 9.03957.95 ± 9.1820.867
 Male, n (%)353 (73.1)1385 (73.9)0.701
Behavioral
 Smoking, n (%)215 (44.5)832 (44.4)0.971
 Drinking, n (%)85 (17.6)331 (17.7)0.97
Physical
 BMI, kg/m226.07 ± 3.56426.07 ± 3.5040.985
 SBP, mmHg129.64 ± 14.982130.5 ± 16.4850.27
 DBP, mmHg77.67 ± 9.91377.8 ± 10.6140.81
Medical history, n (%)
 Hypertension299 (61.9)1208 (64.5)0.29
 Hyperlipidemia209 (43.3)812 (43.4)0.974
 History of MI50 (10.4)201 (10.7)0.81
 History of stroke29 (6.0)144 (7.7)0.206
 Family history of CAD62 (12.8)260 (13.9)0.551
 Previous PCI79 (16.4)317 (16.9)0.766
 Diagnosed DM, years7.82 ± 3.736.58 ± 3.942< 0.001
Clinical presentation, n (%)
 Stable CAD52 (10.8)249 (13.3)0.138
 Unstable angina/NSTEMI352 (72.9)1267 (67.6)0.027
 STEMI79 (16.3)357 (19.1)0.172
Medical treatment, n (%)
 Asprin479 (99.2)1862 (99.4)0.785
 Clopidogrel476 (98)1832 (97.8)0.305
 β-Blocker391 (81)1498 (80)0.632
 Statins473 (97.9)1827 (97.5)0.62
 ACEI/ARB275 (56.9)1028 (54.9)0.419
 Oral hypoglycemic drugs353 (72.9)1322 (70.6)0.321
 Insulin183 (37.9)649 (34.7)0.184
Laboratory results
 TC, mmol/L4.25 ± 1.1114.11 ± 1.0910.015
 LDL-C, mmol/L2.49 ± 0.8412.47 ± 0.890.643
 AIP0.3 ± 0.3560.22 ± 0.292< 0.001
 HbA1c, %8.1 ± 1.2697.4 ± 1.299< 0.001
 hs-CRP, mg/L4.18 ± 6.7084.01 ± 6.8770.614
 Creatinine, μmol/L71.98 ± 17.59571.46 ± 19.9050.604
 GFR, mL/min95.13 ± 20.68095.79 ± 19.6120.515
 LVEF, %61.44 ± 8.23162.09 ± 8.150.118
Number of target vessels0.229
 One, n (%)206 (45.1)856 (45.7) 
 Multivessel, n (%)277 (57.3)1017 (54.3) 
Target vessels
 LM, n (%)17 (3.5)75 (4)0.624
 LAD, n (%)290 (60)1121 (59.9)0.939
 LCX, n (%)720 (34.8)200 (41.4)0.233
 RCA, n (%)212 (43.9)782 (41.8)0.396
 SYNTAX score14.61 ± 6.97112.48 ± 7.162< 0.001
 Minimal stent diameter, mm2.92 ± 0.4572.92 ± 0.460.931
 Average stent length, mm22.27 ± 6.74822.16 ± 6.430.749
Types of stent, n (%)0.338
 First generation DES225 (46.6)827 (44.2) 
 Second generation DES258 (53.4)1046 (55.8) 
  1. Continuous variables were expressed as mean (\({\bar{\text{x}}}\)) ± standard deviation (SD) in case of normal distribution and compared between two groups by two-independent samples t-test. Data were expressed as medians (interquartile ranges) in case of skewed distribution and compared using the Mann–Whitney U-test. Categorical variables are presented as counts (percentages) and compared by Chi-square test
  2. MACCE major adverse cardiac and cerebrovascular event, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, DM diabetes mellitus, MI myocardial infraction, CAD coronary artery disease, PCI percutaneous coronary intervention, NSTEMI non-ST-segment–elevation myocardial infarction, STEMI ST-segment–elevation myocardial infarction, TG triglyceride, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, AIP atherogenic index of plasma, HbA1c glycosylated hemoglobin, hs-CRP high-sensitivity C-reactive protein, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, LM left main, LAD left anterior descending, LCX left circumflex artery, RCA right coronary artery, SYNTAX synergy between PCI with taxus and cardiac surgery, DES drug-eluting stent